12:32 PM EDT, 10/29/2025 (MT Newswires) -- Vor Biopharma ( VOR ) said Wednesday that its partner RemeGen presented 48-week data from a phase 3 study in China showing that telitacicept delivered "consistent" quality-of-life improvement in patients with generalized myasthenia gravis.

All patients treated with telitacicept for 48 weeks achieved an at least two-point improvement in Myasthenia Gravis Activities of Daily Living, with a mean reduction of 7.5 points, the company said.

Vor also said telitacicept showed a favorable safety profile comparable to placebo, with no new safety signals observed, and most adverse events were mild to moderate.

Shares of Vor were down 6.5% in recent Wednesday trading.

Price: 25.17, Change: -1.76, Percent Change: -6.52